Pacritinib
Cat. No.：YN340191
CAS No. ：937272-79-2
| 产品名称: | Pacritinib |
| CAS No.: | 937272-79-2 |
| Chemical Name: | 11-[2-(1-pyrrolidinyl)ethoxy]-14,19-dioxa-5,7,27-triazatetracyclo[19.3.1.12,6.18,12]heptacosa-1(25),2,4,6(27),8,10,12(26),16E,21,23-decaene |
| Synonyms: | SB1518 |
| 分子量: | 472.58 |
| 分子式: | C₂₈H₃₂N₄O₃ |
| SMILES: | C1(COC/C=C/COCC2=C(OCCN3CCCC3)C=CC4=C2)=CC=CC(C5=N/C(NC=C5)=N\4)=C1 |
| 存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
| 运输: | Room temperature in continental US; may vary elsewhere. |
| 产品描述: | Pacritinib 是一种有效的野生型JAK2和JAK2V617F突变型抑制剂，IC50分别为 23 nM 和 19 nM。Pacritinib 也抑制FLT3及其突变型FLT3D835Y，IC50分别为 22 nM 和 6 nM。 |
| IC50和靶点: | [{name:"JAK2V617F:19 nM (IC50)"},{name: "JAK2wt:23 nM (IC50)"},{name: "Tyk2:50 nM (IC50)"},{name: "JAK3:520 nM (IC50)"},{name: "JAK1:1280 nM (IC50)"},{name: "FLT3D835Y:6 nM (IC50)"},{name: "FLT3wt:22 nM (IC50)"}] |
| In Vitro: | |
| In Vivo: | |
| Clinical Trial: | |
| Solvent & Solubility: |
Hart, S., Goh, K.C., Novotny-Diermayr, V., et al.Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemiaBlood Cancer J.1(11),1-9(2011)
Hatzimichael, E., Tsolas, E., and Briasoulis, E.Profile of pacritinib and its potential in the treatment of hematologic disordersJ. Blood Med.5,143-152(2014)
Novotny-Diermayr, V., Hart, S., Goh, K.C., et al.The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AMLBlood Cancer J.2(5),1-10(2012)
